Could metformin be used in patients with diabetes and advanced chronic kidney disease?

Diabetes, Obesity and Metabolism

Volumn 19, Issue 2, 2017, Pages 156-161

  Chowdhury, Tahseen A ^a   Srirathan, Danushan ^a   Abraham, Georgi ^b   Oei, Elizabeth L ^c   Fan, Stanley L ^a   McCafferty, Kieran ^a   Yaqoob, M Magdi ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b PONDICHERRY INSTITUTE OF MEDICAL SCIENCES   (India)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

chronic kidney disease; diabetes; lactic acidosis; metformin

Indexed keywords

GLUCOSE; METFORMIN; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG SAFETY; DRUG URINE LEVEL; DRUG USE; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; EVIDENCE BASED PRACTICE; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; KIDNEY TRANSPLANTATION; LACTIC ACIDOSIS; MODERATE RENAL IMPAIRMENT; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERITONEAL DIALYSIS; REVIEW; SEVERE RENAL IMPAIRMENT; SIDE EFFECT; TREATMENT DURATION; CHEMICALLY INDUCED; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

ACIDOSIS, LACTIC; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; METFORMIN; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 85001740618     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12799     Document Type: Review

References (70)

1. AnonymousDiabetic kidney disease: what does the next era hold? Lancet Diabetes Endocrinol. 2015;3:665.
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease. Lancet. 2015;385:117-171.
3. Castledine C, Davenport A, Dawnay A, et al. UK renal registry 2014, 17th annual report of the Renal Association. Nephron Clin Pract. 2015;129(supp 11).
4. Saran R, Li Y, Robinson B, Ayanian J, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015;66(suppl 1):S1-S306.
5. Rajapurkar MM, John GT, Kirpalani AL, et al. What we know about chronic kidney disease in India: first report of the Indian CKD registry. BMC Nephrol. 2012;13(suppl 2):10.
6. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(suppl 2):s14-s21.
7. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29:855-862.
8. Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83:517-523.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
11. Molitch ME, Adler AI, Flyvbjerg A, et al. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int. 2015;87:20-30.
12. The Renal Association. Detection, monitoring and care of patients with CKD. Feb 2011. http://www.renal.org/guidelines/modules/detection-monitoring-and-care-of-patients-with-ckd#sthash.KOvtHBIu.dpbs. Accessed May 8, 2016.
13. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. CG87, May 2009. https://www.nice.org.uk/guidance/cg87. Accessed May 8, 2016.
14. Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol. 2013;9:529-550.
15. Roussel R, Lorraine J, Rodriguez A, Salaun-Martin C. Overview of data concerning the safe use of antihyperglycemic medications in type 2 diabetes mellitus and chronic kidney disease. Adv Ther. 2015;32:1029-1064.
16. Fioretto P, Steffes M, Sutherland DER, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreatic transplantation. N Engl J Med. 1998;339:69-75.
17. Ghavamian M, Gutch CF, Kopp KF, Kolff WJ. The sad truth about hemodialysis in diabetic nephropathy. JAMA. 1972;222:1386-1389.
18. Drechsler C, Krane V, Ritz E, März W, Wanner C. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation. 2009;120:2421-2428.
19. Zoungas S, Kerr PG, Lui M, Teede HJ. The impact of glycaemic control on outcomes in patients with end-stage renal disease and type 2 diabetes. Nephrology (Carlton). 1997;13:124-127.
20. Morioka T, Emoto M, Tabata T, et al. Glycaemic control is a predictor of survival for diabetic patients on haemodialysis. Diabetes Care. 2001;24:909-913.
21. Oomichi T, Emoto M, Tabata T, et al. Impact of glycaemic control on survival of diabetic patients on chronic regular haemodialysis. Diabetes Care. 2006;29:1496-1500.
22. Wu MS, Yu CC, Yang CW, et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant. 1997;12:2105-2110.
23. Yu CC, Wu MS, Wu CH, Yang CW, et al. Predialysis glycemic control is an independent predictor of clinical outcome in type II diabetics on continuous ambulatory peritoneal dialysis. Perit Dial Int. 1997;17:262-268.
24. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis. 2002;39:297-307.
25. Zinman B, Wanner C, Lachin JM, et al., EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
26. Wanner C, Inzucchi SE, Lachin JM, et al., EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-334.
27. UKPDS Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
28. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
29. Ekström N, Schiöler L, Svensson AM, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open. 2012;2(4), pii: e001076.
30. Panossian Z, Drury PL, Cundy T. Reversible severe deterioration of glycaemic control after withdrawal of metformin treatment. Diabetologia. 2012;55:267-269.
31. Buse JB, De Fronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation. Results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39:198-205.
32. DeFronzo RA, Buse J, Kim T, et al. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia. 2016;59:1645-1654.
33. Scheen AJ. Will delayed release metformin provide better management of diabetes type 2? Expert Opin Pharmacother. 2016;17:627-630.
34. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122:253-270.
35. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59:426-435.
36. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81-98.
37. Sambol NC, Chiang J, Lin ET, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35:1094-1102.
38. Bando K, Ochiai S, Kunimatsu T, et al. Comparison of potential risks of lactic acidosis induction by biguanides in rats. Regul Toxicol Pharmacol. 2010;58:155-160.
39. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf. 2010;33(9):727-740.
40. Eppenga WL, Lalmohamed A, Geerts AF, et al. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population based cohort study. Diabetes Care. 2014;37:2218-2224.
41. Richy FF, Sabido-Espin M, Guedes S, Corvino FA, Gottwald-Hostalek U. Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. Diabetes Care. 2014;37:2291-2295.
42. Bodmer M, Meier C, Krahanbuhl S, Jick SS, Meier CR. Metformin, sulphonylureas or other antidiabetic drugs and the risk of lactic acidosis or hypoglycaemia. Diabetes Care. 2008;31:2086-2091.
43. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes. Cochrane Database Syst Rev. 2010;4:CD002967 doi: 10.1002/14651858.CD002967. pub4.
44. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med. 2004;255:179-187.
45. Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of “metformin-associated lactic acidosis”. Diabetes Obes Metab. 2001;3:195-201.
46. Lalau JD, Race JM. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf. 1999;20:377-384.
47. Lalau JD, Arnouts P, Sharif A, DeBroe ME. Metformin and other antidiabetic agents in renal failure patients. Kidney Int. 2015;87:308-322.
48. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34:1431-1437.
49. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668-2675.
50. Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab. 2013;39:179-190.
51. DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016;65:20-29.
52. Scheen AJ. Personalising metformin therapy: a clinician's perspective. Lancet Diabetes Endocrinol. 2014;2:442-444.
53. Dell'Aglio DM, Perino LJ, Kazzi Z, Abramson J, Schwartz MD, Morgan BW. Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med. 2009;54:818-823.
54. Frid A, Sterner GN, Löndahl M, et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care. 2010;33:1291-1293.
55. Lalau JD, Vermesch A, Hary L, Andrejak M, Isnard F, Quichaud J. Type 2 diabetes in the elderly: and assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol. 1990;28:329-332.
56. Briet C, Saraval-Gross M, Kajbaf F, Fournier A, Hary L, Lalau JD. Erythrocyte metformin levels in patients with type 2 diabetes and varying levels of chronic kidney disease. Clin Kidney J. 2012;5:65-67.
57. Adam WR, O'Brien RC. A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure. Diabet Med. 2014;31:1032-1038.
58. Duong JK, Kumar SS, Kirkpatrick CM, et al. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet. 2013;52:373-384.
59. Hayat JC. The treatment of lactic acidosis in the diabetic patient by peritoneal dialysis using sodium acetate. A report of two cases. Diabetologia. 1974;10:485-487.
60. Lalau JD, Andrejak M, Moriniere P, et al. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol. 1989;27:285-288.
61. Al-Hwiesh AK, Abdul-Rahman IS, El-Deen MA, et al. Metformin in peritoneal dialysis: a pilot experience. Perit Dial Int. 2014;34:368-375.
62. Duong JK, Roberts DM, Furlong TJ, et al. Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab. 2012;14:963-965.
63. Hung SC, Chang YK, Liu JS, et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol. 2015;3:605-614.
64. Lalau JD, Kajbaf F, Arnouts P, de Broe M. Mortality and metformin use in patients with advanced chronic kidney disease. Lancet Diabetes Endocrinol. 2015;3:680-681.
65. Reese PP, Shults J, Bloom RD, et al. Functional status, time to transplantation, and survival benefit of kidney transplantation among wait-listed candidates. Am J Kidney Dis. 2015;66:837-845. Jul 7. pii: S0272-6386(15)00844-6.
66. Palepu S, Prasad GV. New-onset diabetes mellitus after kidney transplantation: current status and future directions. World J Diabetes. 2015;6:445-455.
67. Tufton N, Ahmed S, Rolfe C, Rajkariar R, Byrne C, Chowdhury TA. New onset diabetes after renal transplantation. Diabet Med. 2015;31:1284-1292.
68. Stephen J, Anderson-Haag TL, Gustafsin S, Snyder JJ, Kasiske BL, Israni AK. Metformin use in kidney transplant recipients in the United States: an observational study. Am J Nephrol. 2014;40:546-553.
69. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149.
70. Cohen AS, Edelstein EL. Sick-day management for the home care client with diabetes. Home Healthc Nurse. 2005;23:717-724.